Wardlaw JM, Warlow CP, Counsell C
Systematic review of evidence on thrombolytic therapy for acute
(Aug) 350:607-614 1997
Because of a
showing that early administration of tissue plasminogen activator may be
acute stroke the US FDA approved t-PA for this indication. However, the
takes a more sober view, and points out that the benefits of t-PA are not
the risk of hemorrhage is indeed increased, that the risk of bleeding may be
with concomitant aspirin ingestion (and many such patients will be taking
that most typical patients will not be eligible for such therapy.
The abstract of this paper is available from the National Library of
click here .